The effect of i.v.[intravenous] bisphosphonate [pamidronic acid] on health-related quality of life (QOL) and skeletal morbidity for newly diagnosed treatment demanding multiple myeloma. A prospective randomised double blinded dose-effective study with cost-utility analysis

Trial Profile

The effect of i.v.[intravenous] bisphosphonate [pamidronic acid] on health-related quality of life (QOL) and skeletal morbidity for newly diagnosed treatment demanding multiple myeloma. A prospective randomised double blinded dose-effective study with cost-utility analysis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2010

At a glance

  • Drugs Pamidronic acid (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2010 Results published in the Lancet Oncology.
    • 09 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top